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Abstract
Aims Heart failure (HF) is a clinical syndrome with signiﬁcant social and economic burden. We aimed to estimate the burden
of HF in mainland Portugal over a 22-year time horizon, between 2014 and 2036.
Methods and results Heart failure burden was measured in disability-adjusted life years (DALYs), resulting from the sum of
years of life lost (YLL) due to premature death and years lost due to disability (YLD). YLL were estimated based on the Portu-
guese mortality rates reported by the European Detailed Mortality Database. For YLD, disease duration and the overall inci-
dence were estimated using an epidemiological model developed by the World Health Organization (DISMOD II). Disability
weights were retrieved from published literature. The impact of ageing was estimated with a shift-share analysis using ofﬁcial
demographic projections. In 2014, 4688 deaths were attributed to HF, corresponding to 4.7% of the total deaths in mainland
Portugal. DALYs totalled 21 162, 53.9% due to premature death (YLL: 11 398) and 46.1% due to disability (YLD: 9765). Consid-
ering only population ageing over a 22-year horizon, the deaths and burden of HF are expected to increase by 73.0% and
27.9%, respectively, reaching 8112 deaths and 27 059 DALYs lost due to HF in 2036. DALY’s growth is mainly driven by the
increase of YLL, whose contribution to overall burden will increase to 62.0%.
Conclusions Heart failure is an emerging and growing health problem where signiﬁcant health gains may be obtained. The
projected signiﬁcant increase of HF burden highlights the need to set HF as a priority for healthcare system.
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Introduction
Heart failure (HF) is a clinical syndrome characterized by typ-
ical symptoms that may be accompanied by signs caused by a
structural and/or functional cardiac abnormality, resulting in
a reduced cardiac output and/or elevated intracardiac pres-
sures at rest or during stress.1 HF may have different aetiol-
ogies such as coronary artery disease, valvular heart
disease, and hypertension.2 Paradoxically, the development
of therapeutic interventions that improved the prognosis of
the above-mentioned aetiological conditions by reducing
the associated mortality may have contributed to increase
HF prevalence.3 In addition, the currently available medicines
and devices for the treatment of HF with reduced ejection
fraction itself allowed the achievement of striking improve-
ments in the management of HF, further contributing to the
increased overall survival of these patients and, therefore,
to the increased prevalence of HF.3
Heart failure is known to have an overall signiﬁcant social
and economic burden.4 However, detailed characterization
of the current and future magnitude of this health problem
is scarce. This information is of paramount importance for
all stakeholders in general, and for policymakers in particular,
which have to prioritize health interventions at a regional or
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country level. Furthermore, population ageing and the in-
creasing prevalence of HF, particularly among the elderly, will
pose additional challenges in the management of HF.
In this study, we estimated the current burden of HF in
mainland Portugal as well as the projected HF burden for
the following 22 years to estimate the future impact of ageing
on the burden of the disease.
Methods
We performed a two-phase estimation. First, we estimated the
burden of HF inmainland Portugal in 2014. Second,we estimated
the burden of HF for the following 22 years (from 2015 to 2036).
Burden of heart failure in mainland Portugal in
2014
The burden of disease was estimated in disability-adjusted
life years (DALYs), a measure, expressed in time, of the
amount of health lost due to disability or premature death
generated by the disease. DALYs include two components5:
(i) years of life lost (YLL) due to premature death, with time
lost estimated as the difference between age at death and
standard life expectancy for that age and (ii) years lost due
to disability (YLD), which considers time spent with disability.
This methodology uses epidemiological data, including dis-
ease incidence by severity stages, duration of each stage,
and patient mortality patterns.6
In particular, the number of DALYs lost by an individual was
estimated using the following equation7:
DALY ¼ ∫
aþL
a
DCxeβxer xað Þdx;
where
a initial age;
L length of disability or YLL due to premature death;
D coefﬁcient of disability, between 0 (without any disabil-
ity, perfect health) and 1 (total disability or death);
C constant—correction for age (0.04);
x age, varies between a and a + L;
β parameter from the rule for age correction (0.1658)8; and
r rate of time discount (3%).
In the calculation of DALYs, a discount rate of 3% and an
age-differentiated weighting were used, in which more
weight was given to intermediate age groups (between 20
and 50, when people tend to take care of children) in com-
parison with younger and older groups.6
Years of life lost due to premature death
The YLL due to HF mortality refer to the 2014 mainland Portu-
guese population aged 25 years and over. In addition, the pro-
portion of overall YLL due to HF mortality was also estimated.
For this estimation, data on the number of deaths and standard
life expectancy, by sex and age group, are needed. The overall
mortality data were obtained from the National Statistics Insti-
tute, which has access to all death certiﬁcates in Portugal.8Mor-
tality rates due to HF in Portugal were available in the European
Detailed Mortality Database of the World Health Organization
(WHO) Regional Ofﬁce for Europe.9 To increase robustness,
we considered the average mortality rate due to HF for the last
3 years (2012–2014) (Supporting Information, Table S1). Na-
tional rates were then applied to the population resident in
mainland Portugal in 2014, according to the ofﬁcial estimations
of Statistics Portugal.10 The standard life expectancy was
obtained from the mortality tables adopted by the WHO as a
reference standard.11
Years lost due to disability
For the estimation of YLD, incidence, duration of disease, and
HF disability weights by sex, age group, and disability class are
needed. We assumed that patients with New York Heart As-
sociation (NYHA) Class I have no disability. Therefore, YLD
were estimated for patients with HF NYHA Classes II–IV.
In the absence of robust and direct evidence on the inci-
dence and duration of HF in Portugal, we used the DISMOD
II model, a tool developed by the WHO,12 to estimate these
data, by sex and age group. This model ensures internal con-
sistency between epidemiological parameters of the disease:
incidence rates, prevalence, remission, lethality, mortality or
relative risk of mortality, and disease duration.
The model baseline population was calibrated with the res-
ident population of mainland Portugal in 201410 and with the
2013–2015 life table.13 Afterwards, the model requires a min-
imum of three disease-speciﬁc inputs, which in this case were
as follows: (i) prevalence; (ii) remission rate; and (iii) relative
mortality risk due to HF.
Data on chronic HF NYHA Classes II–IV prevalence in main-
land Portugal in 2014 (Supporting Information, Table S2)
were derived from the distribution of individual patient data
found in the Portuguese landmark study on HF prevalence
(EPICA study),2 a community-based epidemiological survey
conducted in 1998–2000 and involving 5434 subjects older
than 25 years attending primary care centres. The main base-
line characteristics of HF patients identiﬁed in the EPICA
study are shown in Supporting Information, Table S3.
In 2014, the estimated overall prevalence of chronic HF in
Portuguese population aged 25 and above was 5.2% (95% CI:
4.5–5.8), 65.4% of which refer to patients with HF NYHA
Classes II–IV. In our study, we assumed that HF prevalence
at or below 25 years old was zero (as this population was
not evaluated in the EPICA study).
The HF remission rate used in the model was also assumed
to be null due to the rarity of chronic HF conditions that re-
solve completely without any sequelae.
The HF mortality risks used in the model were derived
from the study by Muntwyler et al.,14 which prospectively
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included 411 consecutive patients with HF NYHA Classes II–IV
enrolled in primary care ofﬁces throughout Switzerland. In
this study, the standardized mortality ratios were 3.6 (95%
CI: 2.6–5.1) and 2.2 (95% CI: 1.4–3.4) for men and women, re-
spectively. These standardized ratios were used in the model
as proxies of the HF relative mortality risks.
The outputs on the incidence and HF duration, by sex and
age group, estimated by the DISMOD II model are shown in
Supporting Information, Table S4.
The HF disability weights, also needed for the YLD estima-
tion, were retrieved from the Global Burden of Disease 2015
study.15 In the Global Burden of Disease study, HF was classi-
ﬁed as mild, moderate, and severe. Because of the similarities
in the disease severity deﬁnitions, these classes were consid-
ered as proxies for the II, III, and IV NYHA functional classes,
respectively. Following these assumptions, the disability
weights attributed to NYHA II, III, and IV were 0.041 (95%
CI: 0.026–0.062), 0.072 (95% CI: 0.047–0.103), and 0.179
(95% CI: 0.122–0.251), respectively.
We assumed that the distribution of the incident cases by
NYHA class was proportional to the prevalent cases, as re-
ported in the EPICA study2 (Supporting Information, Table S5).
In the absence of robust data, we considered that disease
duration was independent of the NYHA class. The disability
weights were applied to the incident cases estimated by the
DISMOD II model, by sex, age group, and NYHA class.
Projection of the future burden of heart failure in
a 22-year time horizon
For the YLL and YLD projections, we used the shift-share
methodology.16 This method allows to analyse the isolated
demographic effect on the disease prevalence and burden,
keeping everything else constant. In order to apply the meth-
odology, we ﬁrst computed the YLL and YLD rates in 2014 by
sex and age group. We then applied these rates to the resi-
dent population projections, by sex and age group, from
2015 to 2036.9,17 This methodology implies that the rates of
incidence and mortality, by age and sex, as well as disease du-
ration are constant over time. In other words, the evolution
of HF burden depends only on the changes occurring in the
demographic composition of the population over time.
Results
Current burden of heart failure in mainland
Portugal
Years of life lost due to premature death
The distribution of deaths from all causes and from HF, by sex
and age group, is shown in Supporting Information, Figure S1
and S2, respectively. The total number of deaths attributable
to HF in 2014 was 4688 (66.8% in women), which corre-
sponds to 4.7% of overall mortality in Portugal (Table 1).
Based on these results and the standard life expectancy, we
estimated that in mainland Portugal in 2014, there were
11 398 YLL lost due to HF (60.9% in women), which corre-
sponds to 2.4% of total YLL due to overall mortality (Table 1).
Figure 1 shows the distribution of YLL due to HF, by sex and
age group.
Years lost due to disability
In mainland Portugal in 2014, the YLD due to HF totalled 9765
YLD (52.4% in women). Figure 2 shows the distribution of YLD
due to HF, by sex and age group.
Disability-adjusted life years
The overall burden of HF in mainland Portugal in 2014 was
21 162 DALYs (57.0% in women), corresponding to the sum
of YLL and YLD. The relative contribution of the YLL and YLD
to the overall burden of HF is different according to gender.
The YLL account for 48.9% and 57.6% of the DALY in men
and women, respectively.
Future burden of heart failure in mainland
Portugal
Mortality due to HF is expected to increase by 73.0% in the
next 20 years (with 8112 deaths for HF in 2036) as a conse-
quence of both HF mortality rate being higher in the older
population and population ageing. The YLL are expected to in-
crease by 47.3% (reaching 16 788 YLL in 2036; Figures 3 and 4)
due to the increased mortality, albeit this increment is lower
than the mortality increment.
By 2036, The YLD are expected to increase by 5.2%
(reaching 10 271 YLD in 2036; Figures 3 and 4). Here, the
mean YLD per incident HF case will decrease due to popula-
tion ageing. This result is a consequence of lower disease du-
ration in older population.
Overall, the burden of HF in mainland Portugal will in-
crease by 27.9% in a 22-year time horizon, going from
21 162 DALYs in 2014 to 27 059 DALYs in 2036. The relative
contribution of YLL to the overall burden of HF will increase
from 53.9% in 2014 to 62.0% in 2036 (Figure 4).
Table 1 Mortality and YLL prematurely due to HF, comparing with
mortality and YLL of all causes. Portugal mainland, 2014
Deaths due to HF YLL due to HF
Number
% of all-
cause deaths Number
% of all-
cause YLL
Male 1557 3.1 4454 1.6
Female 3130 6.4 6944 3.6
Overall 4688 4.7 11 398 2.4
HF, heart failure; YLL, years of life lost.
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Figure 1 Years of life lost due to heart failure, by sex and age group, in mainland Portugal in 2014.
Figure 2 Years lost due to disability of heart failure in mainland Portugal in 2014, by sex and age group.
Figure 3 Increase of heart failure burden in Portugal mainland, from 2014 to 2036, according to sex and type of disability-adjusted life years. YLD,
years lost due to disability; YLL, years of life lost.
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Discussion
Heart failure is a clinical syndrome with many different aetiol-
ogies, usually representing a late stage in heart diseases. It is
possible that healthcare improvements in the management
of HF aetiologic factors and HF with reduced ejection fraction
treatment, as well as population ageing, may have contrib-
uted to the increase prevalence of HF. Currently, in mainland
Portugal, HF is responsible for 4.7% of all deaths and 2.4% of
all YLL (almost 11 400 years lost in 2014 due to premature
death). The relative weight of HF in overall YLL (2.4%) is about
half the weight in overall mortality (4.7%), which can be ex-
plained by the fact that, on average, deaths from HF occur
at older ages in comparison with deaths from other causes.
In terms of disability, it was estimated that about 9800 years
of life have been lost in 2014 due to disability attributable to
HF. Overall, the burden of HF was estimated at 21 162 DALYs.
We found that the overall burden in women is overall
higher than in men (57% vs. 43%). The main driver of this dif-
ference is the higher contribution of YLL for the overall bur-
den in women than in men (61% vs. 39%). Sex differences
in YLL estimation are a consequence of the higher mortality
rate of HF in the very old population (80+ years; Supporting
Information, Table S1), two-thirds of which are women. In
contrast, the distribution of YLD by sex is more balanced
(52% vs. 48% in women and men, respectively) due to net re-
sult of two mechanisms with opposite effects. From one side,
HF incidence is higher in men in relatively younger population
(<74 years; Supporting Information, Table S4), leading to an
overall higher disease duration among men. Furthermore,
the age weighting in our study attributes a higher disability
to younger individuals. On the other side, there is a higher in-
cidence of HF in the very old population, most of which are
women.
The projection for disease burden over a 20-year time ho-
rizon suggests a 27.9% increase in the overall burden of HF,
mostly due to the increase in the years lost due to premature
death. It should be highlighted that this increment of YLL due
to HF is lower than the overall expected mortality increment,
resulting in a decreasing YLL per death. This is because more
deaths are occurring in the elder population to which we at-
tributed lower social weight (i.e. society values less deaths oc-
curring in elder population than deaths occurring in younger
population).
Our results overlap with the literature in which HF is pre-
sented as an emergent public health problem, with increasing
relevance.18–20 The present results are also in line with a re-
cent study by Conrad et al.21 that retrospectively assessed
temporal trends in incidence and prevalence of HF in a large
general population cohort from the UK. The authors found
that absolute incidence and prevalence of HF increased by
13% and 23%, respectively, in the last 13 years (from 2002
to 2014). In this study, ageing was one of the main reasons
for the HF burden increase. In our study, we estimated for
the coming years an annual average absolute increase of
1.6% in HF incidence due to ageing.
We have conducted other recent studies using similar
methodologies to evaluate the burden of other cardiovascu-
lar diseases, risk factors, and oncological diseases in
Portugal. Although we acknowledge the limitations of this
type of indirect comparisons, the burden associated with HF
reported in this study is roughly half and two-thirds the bur-
den attributed to alcohol22 consumption and lung cancer,23
respectively; it is similar to the burden associated with atrial
ﬁbrillation24 and female breast cancer25 and twice the burden
associated with hypercholesterolaemia.26 All together, these
results emphasize the need of urgent prioritization of HF in
the health agenda, taking into account the increasing
Figure 4 Relative proportions of disability-adjusted life years in 2014 and 2036, according to the gender and component of disability-adjusted life
years. YLD, years lost due to disability; YLL, years of life lost.
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prevalence of HF, the high morbidity and mortality, and the
socio-economic burden for patients, families, and society.
Our study has several limitations. During the execution of
this study, we found a substantial lack of HF epidemiological
data for the Portuguese population, in particular incidence
and disease duration. To overcome this limitation, we used
a model developed by the WHO12 (DISMOD II model) to esti-
mate these data. DISMOD model is a software tool initially
developed for burden of disease analysis.27 The model ex-
ploits the interdependency between disease incidence, prev-
alence, remission, case fatality, and mortality to estimate
missing epidemiological information. Although the internal
estimates of the model are mathematically consistent, in
some occasions, the epidemiological results obtained may
be inconsistent with the expected disease pattern. To over-
come these inconsistencies, the model allows for several ad-
justment options (e.g. ﬁtting mathematical curves,
interpolation methods, moving average, and application of
other disease age patterns). The more accurate epidemiolog-
ical inputs used, the more accurate estimations are calculated
by the model. As previously mentioned, the HF epidemiolog-
ical data in Portugal are scarce, and therefore, we had to
make some assumptions to calibrate DISMOD model (such
as a null HF prevalence in the population younger than
25 years old, a null HF remission rate, lack of disability among
patients with NYHA Class I, similar distribution by NYHA class
for incident and prevalent cases, and disease duration inde-
pendency from NYHA class). These assumptions may have
led to less accurate estimates. However, we anticipate that
the errors that may have been incorporated tend to go in op-
posite directions. For instance, assuming no disability for
NYHA I leads to an underestimation of the burden while con-
sidering null remission rate leads to its overestimation.
Most epidemiological data used in our study were derive
from the analysis of individual patient data from the Portu-
guese landmark study on HF prevalence (EPICA study).2 How-
ever, this study has several limitations for the purpose of the
present study. First, the EPICA study was conducted in 1998–
2000, and signiﬁcant prevalence changes may have occurred.
Second, it only included individuals aged 25 years or older.
We assumed that the prevalence rate in the age group be-
tween 0 and 25 years was zero. Third, the EPICA study esti-
mated the prevalence of chronic HF among people
attending primary care centres, excluding patients with acute
HF and patients followed at tertiary referral hospitals. The ep-
idemiological estimations from EPICA study included in the
analysis should therefore be interpreted as conservative.
Fourth, the potential impact of some externalities on HF bur-
den was not considered for the purpose of epidemiological
estimations. For example, it has been shown that economic
and ﬁnancial crisis affect cardiovascular morbidity and mor-
tality through a complex interaction of several components
(from prevention to detection and treatment).28,29 The Great
Recession in Portugal led to austerity measures between
2011 and 2014 and may have had an impact on cardiovascu-
lar burden in general and in HF in particular.
We believe that the mortality attributed to HF, based on
the International Classiﬁcation of Disease codes (10th ver-
sion) present in the European Detailed Mortality Database,8
may be underestimated. It is possible that the cause of death
is linked to the cause (e.g. coronary artery disease and cardio-
myopathy) and not the consequence (HF). The proportion of
sudden deaths related to HF may also be underestimated.
Therefore, the data presented for YLL due to premature
death may also be underestimated.
A further limitation of this study is that time changes in the
distribution of incidence among NYHA classes, mortality rate,
and disease duration were not included in the projections. In
other words, our estimation of future burden of HF only ac-
counts for the demographic changes (i.e. population ageing)
considering everything else constant.
In conclusion, the burden of HF is expected to increase by
28% between 2014 and 2036, reaching 27 059 DALYs in 2036.
We estimate that in 2036, YLL will represent 62% of DALY due
to HF (compared with 54% in 2014). These results indicate
that HF is an emerging and growing health problem where
signiﬁcant health gains may be obtained. The projected signif-
icant increase of the burden of HF in the following years high-
lights the need to set HF as a priority for the healthcare
system. In Portugal, the Ministry of Health acknowledged
the current and future health impact of HF and has recently
decided to create a dedicated working group to implement
an integrated management of HF in Portugal.30
Acknowledgements
We thank the investigators of EPICA study for giving access to
individual patient data.
Conﬂict of interest
C.F. has received consulting and speaker fees from Servier
Portugal, Novartis, Vifor, Bayer, and Orion. M.G., R.A., F.F.,
J.C., D.C., P.B., and M.B. have no conﬂict of interest to
declare.
Funding
This study was supported by Novartis Farma, Produtos
Farmacêuticos SA through an unrestricted grant to the Re-
search and Development Association of Lisbon University
School of Medicine (AIDFM). Funding was independent of
the study outcomes. The promoter did not participate in
any phase of the study.
6 M. Gouveia et al.
ESC Heart Failure (2019)
DOI: 10.1002/ehf2.12399
Ethical approval
Not required. No experiments involving animals or humans
were conducted for the purpose of this study.
Supporting information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Figure S1. mortality for all causes by sex and age group, in
mainland portugal in 2014.
Figure S2. mortality for heart failure by sex and age group, in
mainland portugal in 2014.
Table S1. heart failure mortality rate per 100,000 inhabitants
in mainland portugal (average 2012-2014).
Table S2. heart failure (nyha class ii-iv) prevalence rates esti-
mates by sex and age group, in mainland portugal in 2014.
Table S3. baseline characteristics of heart failure patients
identiﬁed in the epica study.
Table S4. estimates of heart failure incidence and disease du-
ration by sex and age group, in portugal mainland in 2014.
Table S5. distribution of heart failure incident cases by new
york heart association functional classes and age group.
References
1. Ponikowski P, Voors AA, Anker SD,
Bueno H, Cleland JGF, Coats AJS, Falk
V, González-Juanatey JR, Harjola VP,
Jankowska EA, Jessup M, Linde C,
Nihoyannopoulos P, Parissis JT, Pieske
B, Riley JP, Rosano GMC, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer
P, ESC Scientiﬁc Document Group. ESC
guidelines for the diagnosis and treat-
ment of acute and chronic heart failure:
the Task Force for the diagnosis and
treatment of acute and chronic heart
failure of the European Society of Cardi-
ology (ESC) developed with the special
contribution of the Heart Failure Associ-
ation (HFA) of the ESC. Eur Heart J
2016; 37: 2129–2200.
2. Ceia F, Fonseca C, Mota T, Morais H,
Matias F, de Sousa A, Oliveira A, EPICA
Investigators. Prevalence of chronic
heart failure in Southwestern Europe:
the EPICA study. Eur J Heart Fail 2002;
4: 531–539.
3. Braunwald E. Heart failure. JACC Heart
Fail 2013; 1: 1–20.
4. Ponikowski P, Anker SD, AlHabib KF,
Cowie MR, Force TL, Hu S, Jaarsma T,
Krum H, Rastogi V, Rohde LE, Samal
UC, Shimokawa H, Budi Siswanto B,
Sliwa K, Filippatos G. Heart failure:
preventing disease and death world-
wide. ESC Heart Fail 2014; 1: 4–25.
5. World Health Organization. Metrics:
disability-adjusted life year (DALY).
http://www.who.int (6 April 2016).
6. Murray CJ. Quantifying the burden of
disease: the technical basis for
disability-adjusted life years. Bull World
Health Organ 1994; 72: 429–445.
7. Mathers CD, Salomon JA, Ezzati M, Begg
S, Lopez AD. Sensitivity and uncertainty
analyses for burden of disease and risk
factor estimates. In Lopez AD, Mathers
CD, Ezzati M, Murray CJL, Jamison DT,
eds. Global Burden of Disease and Risk
Factors. New York: Oxford University
Press; 2006. p399–426.
8. Statistics Portugal. Webpage of Statistics
of Portugal: Óbitos (N.°) por Local de
residência (Distrito/Região), Sexo e
Idade; Anual [Internet]. Lisboa: Instituto
Nacional de Estatística; 2016. https://
www.ine.pt (6 April 2016).
9. World Health Organization Regional Of-
ﬁce for Europe. European detailed mor-
tality database. http://data.euro.who.
int/dmdb/ (12 December 2016).
10. Statistics Portugal. Webpage of Statistics
of Portugal: População residente (N.°)
por Local de residência (NUTS - 2013),
Sexo e Grupo etário; Anual [Internet].
Lisboa: Instituto Nacional de Estatística;
2016. https://www.ine.pt (6 April
2016).
11. World Health Organization. Global
health observatory data repository.
http://apps.who.int/gho/data/view.
main.LIFEREGIONGLOBAL?lang=en
(7 March 2018).
12. Barendregt JJ. DisMod II version 1.01. In
Global Programme on Evidence for Health
Policy; 2001.
13. Statistics Portugal. Tábua Completa de
Mortalidade para Portugal - 2013–2015.
Lisboa: Instituto Nacional de Estatística;
2016. https://www.ine.pt (6 April
2016).
14. Muntwyler J, Abetel G, Gruner C,
Follath F. One-year mortality among un-
selected outpatients with heart failure.
Eur Heart J 2002; 23: 1861–1866.
15. Global, regional, and national incidence,
prevalence, and years lived with disabil-
ity for 310 diseases and injuries, 1990-
2015: a systematic analysis for the
Global Burden of Disease Study 2015.
Lancet 2016; 388: 1545–1602.
16. Esteban-Marquillas JM. A reinterpreta-
tion of shift-share analysis. Regional and
Urban Economics 1972; 2: 249–261.
17. Statistics of Portugal. Projeções de
população residente 2012–2060. Lisboa:
Instituto Nacional de Estatística; 2016.
https://www.ine.pt (6 April 2016).
18. Ambrosy AP, Fonarow GC, Butler J,
Chioncel O, Greene SJ, Vaduganathan
M, Nodari S, Lam CSP, Sato N, Shah
AN, Gheorghiade M. The global health
and economic burden of hospitalizations
for heart failure: lessons learned from
hospitalized heart failure registries. J
Am Coll Cardiol 2014; 63: 1123–1133.
19. Fonseca C, Brito D, Cernadas R, Ferreira
J, Franco F, Rodrigues T, Morais J, Silva
Cardoso J. For the improvement of heart
failure treatment in Portugal—consen-
sus statement. Rev Port Cardiol 2017;
36: 1–8.
20. Fonseca C, Brás D, Araújo I, Ceia F.
Heart failure in numbers: estimates for
the 21st century in Portugal. Rev Port
Cardiol 2018; 37: 97–104.
21. Conrad N, Judge A, Tran J, Mohseni H,
Hedgecott D, Crespillo AP, Allison M,
Hemingway H, Cleland JG, McMurray
JJV, Rahimi K. Temporal trends and pat-
terns in heart failure incidence: a
population-based study of 4 million indi-
viduals. Lancet 2018; 391: 572–580.
22. Cortez-Pinto H, Gouveia M, dos Santos
Pinheiro L, Costa J, Borges M, Vaz CA.
The burden of disease and the cost of
illness attributable to alcohol drinking
—results of a national study. Alcohol
Clin Exp Res 2010; 34: 1442–1449.
23. Borges M, Gouveia M, Alarcão J, Sousa
R, Teixeira E, Barata F, Laranjeira E,
Lopes F, Parente B, Pinheiro L, Vaz-
Carneiro A, Costa J. Cost and burden of
non-small cell lung cancer’s in
Portugal. Value Health 2014; 17: A626.
24. Gouveia M, Costa J, Alarcão J, Augusto
M, Caldeira D, Pinheiro L, Vaz Carneiro
A, Borges M. Burden of disease and cost
of illness of atrial ﬁbrillation in Portugal.
Rev Port Cardiol 2015; 34: 1–11.
25. Sousa R, Fiorentino F, Alarcão J, Lopes
Pereira C, Jesus G, Costa J, Gouveia M,
Borges M. Female breast cancer: burden
of disease in Portugal. Value Health
2015; 18: A489.
Burden of heart failure in Portugal 7
ESC Heart Failure (2019)
DOI: 10.1002/ehf2.12399
26. Gouveia M, Borges M, Augusto M,
Caldeira D, Alarcão J, Pinheiro L, Sousa
R, Fareleira F, Ascenção R, Costa J,
Laires P, Fiuza M, Dias NC, Martins S,
Belo A, Vaz-Carneiro A. Cost and burden
of hypercholesterolemia in Portugal.
Value Health 2014; 17: A339.
27. Barendregt JJ, van Oortmarssen GJ,
Vos T, Murray CJ. A generic model
for the assessment of disease epidemi-
ology: the computational basis of
DisMod II. Popul Health Metr 2003;
1: 4.
28. Tousoulis D. Socioeconomic status and
cardiac disease in Europe: a modern-
day problem in the era of economic cri-
sis. Hellenic J Cardiol 2017; 58: 1–3.
29. Sanidas EA, Papaioannou TG,
Papadopoulos DP, Tatsi K, Velliou M,
Dalianis N, Paizis I, Anastasiadis G,
Kelepesis G, Bonou M, Tsiouﬁs K,
Barbetseas J. The impact of ﬁnancial
crisis on coronary artery disease burden
in Greece. Hellenic J Cardiol 2018; pii:
S1109-9666(17)30548-1.
30. Order no. 4583/2018 [Diário da
República (Portuguese Ofﬁcial Gazette)
no. 90/2018, II Series, of 2018/05/10].
https://dre.pt/web/guest/pesquisa/-/
search/115251143/details/normal?l=1
(4 May 2018).
8 M. Gouveia et al.
ESC Heart Failure (2019)
DOI: 10.1002/ehf2.12399
